Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?

SIMPLE SUMMARY: To summarise the data on the combination of antiangiogenic and immune checkpoints in the treatment of clear-cell renal-cell carcinoma. In this review, we detail the physiopathological rationale of combining tyrosine kinase inhibitors and immunotherapy, and the in vitro and in vivo ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Granet-Vaissiere, Estelle, Lefort, Félix, Domblides, Charlotte, Larroquette, Mathieu, Ravaud, Alain, Bernhard, Jean-Christophe, Gross-Goupil, Marine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954176/
https://www.ncbi.nlm.nih.gov/pubmed/36831392
http://dx.doi.org/10.3390/cancers15041048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954176/
https://www.ncbi.nlm.nih.gov/pubmed/36831392
http://dx.doi.org/10.3390/cancers15041048

Ejemplares similares